Precigen stock price target maintained at $6 by JMP on RRP therapy

JMP Securities reaffirmed its Market Outperform rating and $6 price target for Precigen (PGEN), citing the potential of its PRGN-2012 therapy to transform the treatment of Recurrent Respiratory Papillomatosis (RRP) following a recent patient advocacy event. The firm believes PRGN-2012 could quickly become a standard of care if approved, and the company's $81 million in cash reserves are expected to support operations into 2026; the FDA's decision on PRGN-2012 is expected by August 27, 2025.

Analysis

JMP Securities has reaffirmed its Market Outperform rating and a $6 price target for Precigen Inc. (NASDAQ:PGEN), highlighting a significant potential upside from its current $1.50 valuation, primarily driven by optimism following a patient advocacy event for Recurrent Respiratory Papillomatosis (RRP). This positive stance is underpinned by the company's lead therapeutic candidate, PRGN-2012, which JMP believes could be "transformational" for RRP patients by addressing the underlying disease rather than merely managing symptoms, and potentially establish itself as a standard of care if approved. Despite Precigen's current unprofitability and a "FAIR" overall financial health rating from InvestingPro, the stock has demonstrated strong momentum with a 110% gain over the past six months. The company's financial position is supported by approximately $81 million in cash reserves as of Q1 2025, which JMP analysts estimate will fund operations into 2026, and a robust current ratio of 3.53, indicating strong liquidity. The FDA has accepted the Biologics License Application for PRGN-2012, with a PDUFA review date set for August 27, 2025, and JMP anticipates a "high probability of approval." This sentiment is echoed by other firms: Cantor Fitzgerald raised its target to $5, H.C. Wainwright maintains a Buy with a $6 target, and Stifel reiterated a Buy, citing promising clinical data and PRGN-2012's potential market advantage. Precigen is actively preparing for a potential launch by expanding manufacturing capacity and engaging with healthcare providers.

Key Decisions for Investors

• Investors should closely monitor all communications and developments related to the FDA's review of PRGN-2012, as the PDUFA date of August 27, 2025, represents a critical catalyst for PGEN's valuation.
• Given Precigen's current unprofitable status and significant reliance on the successful approval and commercialization of PRGN-2012, it is essential to evaluate investment exposure in PGEN against individual risk tolerance, considering the binary nature of drug approval outcomes.
• While multiple analysts project substantial upside with price targets ranging from $5 to $6, investors should balance this optimism with the company's "FAIR" financial health rating and the inherent execution risks associated with bringing a new therapy to market.
• Carefully assess Precigen's cash burn rate against its reported $81 million in reserves to ensure sufficient financial runway through the PDUFA date and initial commercialization phase, should PRGN-2012 gain approval.